Table 4.

CTC grades 3 to 5 toxicities



Cumulative incidences

Mean number of events per patient
Category
Nonablative patients, %
Ablative patients, %
P
Nonablative patients
Ablative patients
P
Hematologic     2.3   4.7   < 10-4 
   Neutropenia   58   100   < 10-4  —   —   —  
   Thrombopenia   18   97   < 10-4  —   —   —  
   Rejection   7   0   .008   —   —   —  
Cardiovascular   58   66   .31   0.7   0.8   .28  
Gastrointestinal   8   78   < 10-4  0.1   0.9   < 10-4 
Hemorrhage   1   8   .04   0.01   0.1   .05  
Hepatic   16   49   < 10-4  0.2   1.0   < 10-4 
Infection   58   88   < 10-4  0.9   2.4   < 10-4 
Metabolic   58   74   .04   1.1   1.7   .01  
Neurologic   7   15   .11   0.1   0.2   .09  
Pulmonary   4   14   .04   0.04   0.2   .03  
Renal   12   18   .35   0.2   0.3   .41  
Other
 
12*
 
18
 
.35
 
0.1
 
0.3
 
.08
 


Cumulative incidences

Mean number of events per patient
Category
Nonablative patients, %
Ablative patients, %
P
Nonablative patients
Ablative patients
P
Hematologic     2.3   4.7   < 10-4 
   Neutropenia   58   100   < 10-4  —   —   —  
   Thrombopenia   18   97   < 10-4  —   —   —  
   Rejection   7   0   .008   —   —   —  
Cardiovascular   58   66   .31   0.7   0.8   .28  
Gastrointestinal   8   78   < 10-4  0.1   0.9   < 10-4 
Hemorrhage   1   8   .04   0.01   0.1   .05  
Hepatic   16   49   < 10-4  0.2   1.0   < 10-4 
Infection   58   88   < 10-4  0.9   2.4   < 10-4 
Metabolic   58   74   .04   1.1   1.7   .01  
Neurologic   7   15   .11   0.1   0.2   .09  
Pulmonary   4   14   .04   0.04   0.2   .03  
Renal   12   18   .35   0.2   0.3   .41  
Other
 
12*
 
18
 
.35
 
0.1
 
0.3
 
.08
 

— indicates not done.

*

Hematopoietic cell infusion reactions (n = 5), musculoskeletal events (n = 2), hemolytic-uremic syndrome (HUS, n = 1), and allergic reaction (n = 1)

Dermatological (n = 4), musculoskeletal (n = 4), HUS (n = 3) and hematopoietic cell infusion reactions (n = 2)

or Create an Account

Close Modal
Close Modal